Homozygous sickle cell disease related mortality in Senegal (2011-2020).
Senegal
acute anemia
acute chest syndrome
homozygous sickle cell disease
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
29
05
2021
revised:
15
07
2021
accepted:
19
07
2021
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Homozygous sickle cell disease (HSCD) is characterized by multiorgan morbidity and an increased risk of early death. We aim to describe the mortality rate, causes, and risk factors of death in HSCD between 2011 and 2020. We conducted a retrospective study with a duration of 10 years in the cohort of 2348 HSCD patients. The mortality rate was determined by reporting the number of deaths to the total number of patients followed in the year. Sociodemographic, clinical, biological data and causes of death were studied. Death risk factors were determined by a bivariate analysis comparing deceased and living HSCD patients. The mean age of death was 26 years (3-52). The sex ratio was 1.2. The mortality rate was 2.76%. The death rate was high in 2011 (3.2%) and low in 2020 (0.17%). We observed a significant reduction of mortality of 94.6%. Most of the common causes of death were acute anemia (40%), acute chest syndrome (24.6%), and infections (20%). Risk factors of death were age, vaso-occlusive crises ≥3, acute chest syndrome, blood transfusion, and chronic complications. Mortality among HSCD has significantly decreased over the past 10 years in Senegal, and the main causes of death were acute anemia, acute chest syndrome, and infections.
Identifiants
pubmed: 35845188
doi: 10.1002/jha2.273
pii: JHA2273
pmc: PMC9176000
doi:
Types de publication
Journal Article
Langues
eng
Pagination
711-715Informations de copyright
© 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Cochrane Database Syst Rev. 2020 Jan 16;1:CD007843
pubmed: 31942751
Chest. 2000 May;117(5):1386-92
pubmed: 10807826
Am J Hematol. 2019 May;94(5):E138-E141
pubmed: 30773675
Haematologica. 2017 Apr;102(4):626-636
pubmed: 28104703
PLoS One. 2014 Jul 02;9(7):e99489
pubmed: 24988120
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):259-266
pubmed: 28641096
Am J Hematol. 2018 Sep;93(9):1153-1160
pubmed: 29981283
Med Trop (Mars). 2010 Dec;70(5-6):471-4
pubmed: 21520649
Am J Hematol. 2006 Nov;81(11):858-63
pubmed: 16924640
Nat Rev Dis Primers. 2018 Mar 15;4:18010
pubmed: 29542687
Cochrane Database Syst Rev. 2017 Apr 20;4:CD002202
pubmed: 28426137
Am J Hematol. 2010 Jun;85(6):403-8
pubmed: 20513116
Nephrol Ther. 2014 Feb;10(1):10-6
pubmed: 24113202
Rev Med Interne. 2003 Nov;24(11):711-5
pubmed: 14604747
Rev Med Interne. 2009 Sep;30 Suppl 3:S162-223
pubmed: 19713011
Br J Haematol. 2003 Oct;123(2):359-65
pubmed: 14531921
Br J Haematol. 2012 Nov;159(3):360-7
pubmed: 22967259
Cochrane Database Syst Rev. 2017 Oct 10;10:CD003427
pubmed: 28994899
Pediatr Blood Cancer. 2016 May;63(5):781-5
pubmed: 26840500
Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:183-8
pubmed: 26431903
Int J Gynaecol Obstet. 2012 Dec;119(3):224-6
pubmed: 22986097
Transfus Clin Biol. 2021 May;28(2):143-145
pubmed: 33515732
Am J Prev Med. 2011 Dec;41(6 Suppl 4):S398-405
pubmed: 22099364
Lancet. 2016 Jun 18;387(10037):2565-74
pubmed: 27353687
PLoS One. 2020 Apr 3;15(4):e0229959
pubmed: 32243480
Transfus Clin Biol. 2013 May;20(2):68-71
pubmed: 23597585
Blood. 2010 Apr 29;115(17):3447-52
pubmed: 20194891
PLoS One. 2014 Apr 16;9(4):e94387
pubmed: 24740290
Public Health Rep. 2013 Mar-Apr;128(2):110-6
pubmed: 23450875
Pediatrics. 1989 Sep;84(3):500-8
pubmed: 2671914
Paediatr Int Child Health. 2015;35(4):329-32
pubmed: 26744158
Blood. 2010 Mar 25;115(12):2354-63
pubmed: 19903897